Geneva Capital Management LLC reduced its stake in HealthEquity, Inc. (NASDAQ:HQY – Free Report) by 3.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,106,066 shares of the company’s stock after selling 43,614 shares during the quarter. HealthEquity comprises approximately 2.8% of Geneva Capital Management LLC’s portfolio, making the stock its 10th biggest holding. Geneva Capital Management LLC’s holdings in HealthEquity were worth $97,843,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Hantz Financial Services Inc. grew its stake in HealthEquity by 4.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 5,936 shares of the company’s stock worth $525,000 after buying an additional 272 shares in the last quarter. Danske Bank A S bought a new position in shares of HealthEquity in the 3rd quarter worth $8,141,000. Allworth Financial LP increased its holdings in shares of HealthEquity by 11.2% in the 3rd quarter. Allworth Financial LP now owns 2,741 shares of the company’s stock worth $248,000 after buying an additional 277 shares during the last quarter. Eurizon Capital SGR S.p.A. raised its position in shares of HealthEquity by 34.1% during the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 1,835 shares of the company’s stock valued at $160,000 after buying an additional 467 shares in the last quarter. Finally, Fifth Third Bancorp raised its position in shares of HealthEquity by 0.8% during the 3rd quarter. Fifth Third Bancorp now owns 23,363 shares of the company’s stock valued at $2,067,000 after buying an additional 190 shares in the last quarter. 99.55% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the stock. Barclays lifted their price objective on shares of HealthEquity from $110.00 to $115.00 and gave the stock an “overweight” rating in a report on Friday, September 18th. Raymond James Financial reiterated a “strong-buy” rating on shares of HealthEquity in a research report on Thursday, September 3rd. Telsey Advisory Group set a $111.00 target price on HealthEquity in a research note on Friday, August 28th. BTIG Research restated a “buy” rating and set a $115.00 price target on shares of HealthEquity in a research report on Friday, August 28th. Finally, Deutsche Bank lifted their price target on HealthEquity from $135.00 to $142.00 and gave the stock a “buy” rating in a research note on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $113.53.
Read Our Latest Research Report on HealthEquity
Insider Buying and Selling at HealthEquity
In other news, Director Adrian Dillon sold 7,632 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $104.61, for a total value of $798,383.52. Following the completion of the sale, the director owned 62,395 shares of the company’s stock, valued at approximately $6,527,140.95. This represents a 10.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.60% of the company’s stock.
HealthEquity Price Performance
Shares of HQY opened at $103.46 on Monday. The firm has a market cap of $8.56 billion, a P/E ratio of 37.35, a P/E/G ratio of 1.63 and a beta of 0.22. The stock has a 50 day simple moving average of $96.08 and a two-hundred day simple moving average of $89.97. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.99 and a quick ratio of 2.99. HealthEquity, Inc. has a 1 year low of $72.76 and a 1 year high of $110.26.
HealthEquity (NASDAQ:HQY – Get Free Report) last issued its quarterly earnings results on Thursday, August 27th. The company reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.05. The business had revenue of $350.73 million for the quarter, compared to analysts’ expectations of $349.22 million. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The firm’s revenue was up 95.5% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. On average, analysts forecast that HealthEquity, Inc. will post 3.94 earnings per share for the current fiscal year.
HealthEquity Company Profile
HealthEquity, Inc. provides technology and services for health savings accounts (HSAs) and other consumer-directed benefits. Its platform supports employers, health plans, benefits advisers and individuals in managing health-related accounts and benefits. Alongside HSAs, the company administers flexible spending accounts, health reimbursement arrangements, commuter benefits and other workplace benefit programs. Its services include account administration, payment tools, customer support and investment options for eligible HSA funds.
Featured Stories
- Five stocks we like better than HealthEquity
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY – Free Report).
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.
